Lee Soonhyouk, Hahn Changtae, Seong Eunyoung, Choi Hak Soo
Center for Integrated Smart Sensors, N1, 291 Daehak-ro, Yuseong-gu, Daejeon, South Korea; Megnosis Co., Ltd., 11-3, Techno 1-ro, Yuseong-gu, Daejeon, South Korea.
Department of Psychology, The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, South Korea.
Biosens Bioelectron. 2025 Apr 1;273:117181. doi: 10.1016/j.bios.2025.117181. Epub 2025 Jan 17.
Alzheimer's disease (AD) is a devastating neurodegenerative condition characterized by progressive cognitive decline with currently no effective treatment available. One of the most critical areas in AD research is the identification of reliable biomarkers, which are essential for accurate diagnosis, prognostic assessment, and the development of targeted therapies. In this study, we introduce two novel reactive EEG (rEEG) biomarkers aimed at enhancing the diagnosis of AD and mild cognitive impairment (MCI). These biomarkers, previously unexplored in the literature, offer new insights into differentiating between various cognitive states. The first biomarker demonstrates a significant ability to distinguish between AD patients and normal controls (NC), while also effectively distinguishing MCI patients from NC. The second biomarker is designed to identify a subset of AD patients exhibiting hyperconductivity or hyperactivity, characterized by distinctive neural electrical patterns. A cohort of 90 elderly participants (mean age 76.63 ± 6.08 years) was recruited, including 30 AD patients, 30 individuals with MCI, and 30 NC subjects. Psychiatric diagnoses of participants were made by qualified professionals at Daejeon St. Mary's Hospital, The Catholic University of Korea, utilizing comprehensive neuropsychological assessments. Notably, the rEEG biomarkers achieved accuracies of 95%, 95%, and 98% in distinguishing between AD and NC, AD and MCI, and MCI and NC groups, respectively. These results underscore the potential of rEEG as a highly accurate and reliable diagnostic tool for cognitive impairments, including AD and MCI.
阿尔茨海默病（AD）是一种毁灭性的神经退行性疾病，其特征是进行性认知衰退，目前尚无有效的治疗方法。AD研究中最关键的领域之一是识别可靠的生物标志物，这对于准确诊断、预后评估以及靶向治疗的开发至关重要。在本研究中，我们引入了两种新型反应性脑电图（rEEG）生物标志物，旨在加强对AD和轻度认知障碍（MCI）的诊断。这些生物标志物在文献中此前未被探索过，为区分各种认知状态提供了新的见解。第一种生物标志物显示出在区分AD患者与正常对照（NC）方面具有显著能力，同时也能有效区分MCI患者与NC。第二种生物标志物旨在识别表现出高传导性或多动性的AD患者亚组，其特征为独特的神经电活动模式。招募了90名老年参与者（平均年龄76.63±6.08岁），包括30名AD患者、30名MCI个体和30名NC受试者。韩国天主教大学大田圣玛丽医院的合格专业人员利用全面的神经心理学评估对参与者进行了精神科诊断。值得注意的是，rEEG生物标志物在区分AD与NC、AD与MCI以及MCI与NC组时，准确率分别达到了95%、95%和98%。这些结果强调了rEEG作为一种用于包括AD和MCI在内的认知障碍的高度准确且可靠的诊断工具的潜力。
